Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of Clesacostat in healthy adults
NCT02871037Phase 1Completed
- Sponsor
- Pfizer
- Start
- Aug 2016
- Primary completion
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of clesacostat in Nonalcoholic steatohepatitis (NASH) (5 arms), sponsored by Pfizer. Primary endpoints: Number of Subjects experiencing an Adverse Event, Maximum Observed Plasma Concentration and 6 more. Started Aug 2016; status: completed.
02
Drugs
clesacostat
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT02871037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02871037.